These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 8438456

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy and mechanism of action of rapamycin in presensitized recipients of experimental allografts.
    Chen H, Wu J, Xu D, Luo H, Daloze P.
    Transplant Proc; 1992 Oct; 24(5):1669-70. PubMed ID: 1412790
    [No Abstract] [Full Text] [Related]

  • 4. Rapamycin reverses acute heart, kidney, and pancreas allograft rejection and prevents accelerated heart allograft rejection in the rat.
    Chen H, Wu J, Xu D, Luo H, Daloze P.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):719-20. PubMed ID: 8438454
    [No Abstract] [Full Text] [Related]

  • 5. Rapamycin treatment prevents and/or erases sensitization and abrogates accelerated rejection of vascularized organ allografts.
    Schmidbauer G, Hancock WW, Wasowska BA, Sablinski T, Kupiec-Weglinski JW.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):712-3. PubMed ID: 8438450
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Abrogation of accelerated allograft rejection by intrathymic injection of donor spleen cells is associated with upregulation of donor-reactive IgM, IgG1, and IgG2A, but depression of IgG2B in the circulation and at the graft site.
    Binder J, Hancock WW, Watschinger B, Wasowska B, Sayegh MH, Kupiec-Weglinski JW.
    Transplant Proc; 1995 Feb; 27(1):138-41. PubMed ID: 7878919
    [No Abstract] [Full Text] [Related]

  • 9. Reversal of ongoing rejection of allografts by rapamycin.
    Chen HF, Wu JP, Luo HY, Daloze PM.
    Transplant Proc; 1991 Aug; 23(4):2241-2. PubMed ID: 1871859
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Complete control of humoral and cell-mediated xenoreactions with the combination of leflunomide and cyclosporine.
    Chong AS, Shen J, Xiao F, Blinder L, Foster P, Sankary H, Williams JW.
    Transplant Proc; 1996 Apr; 28(2):684. PubMed ID: 8623344
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Synergism in immunosuppression. 3. Allograft rejection and humoral antibody production in intact and splenectomized mice.
    Gelfand MC, Nowakowski A, Friedman EA, Knepshield JH.
    Transplantation; 1971 Nov; 12(5):377-83. PubMed ID: 4948689
    [No Abstract] [Full Text] [Related]

  • 20. Tacrolimus-based partial conditioning produces stable mixed lymphohematopoietic chimerism and tolerance for cardiac allografts.
    Gammie JS, Li S, Zeevi A, Demetris AJ, Ildstad ST, Pham SM.
    Circulation; 1998 Nov 10; 98(19 Suppl):II163-8; discussion II168-9. PubMed ID: 9852899
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.